Boehringer Ingelheim
For Healthcare Professionals
spiolto

Spiolto

Read more
spiolto

Read more

Early intervention to optimize lung function

01/03/2019  |  Author: Boehringer Ingelheim

The greatest decline in lung function is in GOLD stage 2.4 This fast lung decline in the early stages is also linked to a dramatic reduction in activities and can potentially lead to a downward spiral. Hence it is vital for patients to receive optimum treatment in the early stages of disease.5,6

Document ID: PC-SG-100191

RELATED CONTENT

References
  • 1.
     Pitcairn G et al. J Aerosol Med 2005;3:264-272.
  • 2.
     Anderson A. Int J Chron Obstruct Pulmon Dis 2006;1:251-259.
  • 3.
     Dalby R et al. Med Devices: Evidence and Research 2011;4:145-155.
  • 4.
     Tantucci C et al. Int J Chron Obstruct Pulmon Dis 2012;7:95-99.
  • 5.
     Reardon JZ et al. Am J Med 2006;119(10 suppl 1):S32-37.
  • 6.
     Watz H et al. Eur Respir J 2009;33(2):262-272.

What is Spiolto® Respimat® (tiotropium/olodaterol)?

Tiotropium/olodaterol is approved as once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. It is built on tiotropium, the active ingredient in Spiriva® and is enhanced by olodaterol which was specifically designed to complement the efficacy of tiotropium. Tiotropium/olodaterol provides significant improvements in lung function, COPD symptoms and quality of life over tiotropium – right from the initial stages when suitable patients need maintenance therapy.[1-4]

Tiotropium/olodaterol is administered via Respimat®, the only inhaler available that actively delivers a unique mist. This means the patient just needs to take a slow deep breath to get the medication deep into the lungs.*[5-9]

What is the safety profile of Spiolto® Respimat® (tiotropium/olodaterol)?

Spiolto® Respimat® (tiotropium/olodaterol) has a comparable adverse event profile to the component monotherapies.[10]

Adverse event incidence was generally balanced across all treatment groups, with the majority being mild to moderate in severity.[10]

Spiolto® Respimat® safety and tolerability profile was established in patients treated for up to 52 weeks.[10]

The proportion of patients who discontinued due to adverse events with Spiolto® Respimat® was comparable to that of Spiriva® (tiotropium) and Striverdi® (olodaterol).[10]

The percentage of patients reporting an adverse event with Spiolto® Respimat® was comparable to that of Spiriva®.[10]

For full safety profile, please refer to the Local Prescribing Information.

What are the contraindications of Spiolto® Respimat® (tiotropium/olodaterol)?[4]

Spiolto® Respimat® is contraindicated in patients with hypersensitivity to tiotropium or olodaterol or to any of the excipients.

Spiolto® Respimat® is also contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium.

For information on warnings and precautions, please refer to the Local Prescribing Information.

References
  • [1]
     Maltais F et al. Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax. 2014;69:A186-A187.
  • [2]
     Ferguson F et al. Efficacy of tiotropium+olodaterol in patients with COPD by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523-526.
  • [3]
     Singh D et al. Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;10:1312-1319.
  • [4]
     Spiolto® Respimat® Summary of Product Characteristics, February 2017.
  • [5]
     Newman SP et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of Respimat® with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113:957-963.
  • [6]
     Pitcairn G et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18(3):264-272.
  • [7]
     Dalby R et al. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm. 2004;283:1-9.
  • [8]
     Dalby RN et al. Development of Respimat® SoftMist™ inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145-155.
  • [9]
     Anderson P. Use of Respimat Soft Mist Inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251–259.
  • [10]
     Buhl R et al. Eur Respir J. 2015;45:969-979.
  • [11]
     Spiriva® Respimat® Summary of Product Characteristics January 2017.
  • [12]
     Striverdi® Respimat® Summary of Product Characteristics March 2016.